Opiant Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the 2mg formulation of NARCAN Nasal Spray for opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. NARCAN is partnered with and marketed in the U.S. by privately-held Adapt Pharma.